We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Array (ARRY) Oncology Drug Accepted for Review in the U.S.
Read MoreHide Full Article
Array BioPharma (ARRY - Free Report) announced that the FDA has accepted a New Drug Application (NDA) for its pipeline candidate, binimetinib.
The NDA was submitted in Jun 2016 based on positive results from the phase III trial, NEMO, which compared binimetinib with dacarbazine in unresectable or metastatic NRAS-mutant melanoma patients. The study met its primary endpoint of improving progression-free survival (PFS), compared with dacarbazine treatment.
The FDA has given a Prescription Drug User Fee Act (PDUFA) of Jun 30, 2017. As part of the review process, the agency plans to hold an advisory committee meeting.
We note that Array is currently preparing for an Application Orientation Meeting with the FDA scheduled for Sep 2016. The company plans to discuss the NDA package with the regulatory agency, including the candidate’s clinical risk/benefit profile, at the meeting.
We remind investors that Array regained development and commercialization rights to binimetinib from Novartis Pharma AG (NVS - Free Report) in Mar 2015.
Thereafter, the company entered into a an agreement with Pierre Fabre Medicament SAS, whereby the latter was granted rights to commercialize binimetinib and encorafenib in all countries except the U.S., Canada, Japan, Korea and Israel, where Array retained rights. The agreement became effective in Dec 2015.
Array BioPharma is focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients suffering from cancer. Five registration studies on three cancer candidates – binimetinib (MEK162), encorafenib (LGX818) and selumetinib – are currently underway at the company.
Meanwhile, Array is evaluating binimetinib in several other oncology trials. A phase III trial, COLUMBUS, is evaluating encorafenib, in combination with binimetinib, in patients with BRAF-mutant melanoma. It has also initiated the BEACON trial to study encorafenib, in combination with binimetinib and cetuximab, in patients with BRAFV600E-mutant colorectal cancer. Top-line data from the COLUMBUS trial will be out in the third quarter of 2016.
Array BioPharma currently carries a Zacks Rank #3 (Hold). Some better-ranked health care stocks include Pacira Pharmaceuticals, Inc. (PCRX - Free Report) , and Corcept Therapeutics Incorporated (CORT - Free Report) . Both these stocks sports a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Array (ARRY) Oncology Drug Accepted for Review in the U.S.
Array BioPharma (ARRY - Free Report) announced that the FDA has accepted a New Drug Application (NDA) for its pipeline candidate, binimetinib.
The NDA was submitted in Jun 2016 based on positive results from the phase III trial, NEMO, which compared binimetinib with dacarbazine in unresectable or metastatic NRAS-mutant melanoma patients. The study met its primary endpoint of improving progression-free survival (PFS), compared with dacarbazine treatment.
The FDA has given a Prescription Drug User Fee Act (PDUFA) of Jun 30, 2017. As part of the review process, the agency plans to hold an advisory committee meeting.
We note that Array is currently preparing for an Application Orientation Meeting with the FDA scheduled for Sep 2016. The company plans to discuss the NDA package with the regulatory agency, including the candidate’s clinical risk/benefit profile, at the meeting.
ARRAY BIOPHARMA Price
ARRAY BIOPHARMA Price | ARRAY BIOPHARMA Quote
We remind investors that Array regained development and commercialization rights to binimetinib from Novartis Pharma AG (NVS - Free Report) in Mar 2015.
Thereafter, the company entered into a an agreement with Pierre Fabre Medicament SAS, whereby the latter was granted rights to commercialize binimetinib and encorafenib in all countries except the U.S., Canada, Japan, Korea and Israel, where Array retained rights. The agreement became effective in Dec 2015.
Array BioPharma is focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients suffering from cancer. Five registration studies on three cancer candidates – binimetinib (MEK162), encorafenib (LGX818) and selumetinib – are currently underway at the company.
Meanwhile, Array is evaluating binimetinib in several other oncology trials. A phase III trial, COLUMBUS, is evaluating encorafenib, in combination with binimetinib, in patients with BRAF-mutant melanoma. It has also initiated the BEACON trial to study encorafenib, in combination with binimetinib and cetuximab, in patients with BRAFV600E-mutant colorectal cancer. Top-line data from the COLUMBUS trial will be out in the third quarter of 2016.
Array BioPharma currently carries a Zacks Rank #3 (Hold). Some better-ranked health care stocks include Pacira Pharmaceuticals, Inc. (PCRX - Free Report) , and Corcept Therapeutics Incorporated (CORT - Free Report) . Both these stocks sports a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>